Some p53-binding proteins that can function as arbiters of life and death

Cell Death and Differentiation

Volumn 13, Issue 6, 2006, Pages 984-993

  Braithwaite, Antony W ^a   Del Sal, G ^b   Lu, X ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ASPP; E2F; p53; Pin1; YB1

Indexed keywords

ANKYRIN; APOPTOSIS STIMULATING PROTEIN OF P53; BINDING PROTEIN; DNA; E1A PROTEIN; ISOMERASE; PROLY ISOMERASE PIN1; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; PROTEIN SH3; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR E2F5; TRANSCRIPTION FACTOR E2F6; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

APOPTOSIS; BREAST CARCINOMA; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL TRANSFORMATION; COLORECTAL CANCER; DISEASE MARKER; DNA DAMAGE; GENE ACTIVITY; GENE INACTIVATION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; UTERINE CERVIX CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PEPTIDYLPROLYL ISOMERASE; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646817444     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401924     Document Type: Review

References (80)

1. Prives C and Hall PA (1999) The p53 pathway. J. Path. 187: 112-126.
2. Perrem K, Rayner J, Voss T, Sturzbecher H, Jackson P and Braithwaite A (1995) p53 represses SV40 transcription by preventing formation of transcription complexes. Oncogene 11: 1299-1307.
3. Zilfou J, Hoffman WH, Sank M, George DL and Murphy M (2001) The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome mediated degradation. Mol. Cell. Biochem. 21: 3974-985.
4. Braithwaite A, Royds J and Jackson P (2005) The p53 story: Layers of complexity. Carcinogenesis 26: 1161-1169.
5. Logan N, Graham A, Zhao X, Fisher R, Maiti B, Leone G and La Thangue NB (2005) E2F-8: An E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene 24: 5000-5004.
6. Loughran O and La Thangue NB (2002) E2F proteins. Curr. Biol. 12: R377.
7. O'Connor DJ, Lam EW, Griffin S, Zhong S, Leighton LC, Burbidge SA and Lu X (1995) Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J. 14: 6184-6192.
8. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S and Lu X (2002) Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol. Cell. Biol. 22: 78-93.
9. Fogal V, Hsieh JK, Royer C, Zhong S and Lu X (2005) Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. EMBO J. 24: 2768-2782.
10. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E and Xie D (1997) Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36: 10117-10124.
11. Price B, Hughes-Davies L and Park S (1995) cdk2 kinase phosphorylates serine315 of human p53 in vitro. Oncogene 11: 73-80.
12. Wang Y, Schwedes J, Parks D, Mann K and Tegtmeyer P (1995) Interaction of p53 with its concensus DNA-binding site. Mol. Cell. Biol. 15: 2157-2165.
13. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czemiak BA and Sen S (2004) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 36: 55-62.
14. DeGregori J, Kowalik T and Nevins JR (1995) Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15: 4215-4224.
15. Leone G, DeGregori J, Jakoi L, Cook JG and Nevins JR (1999) Collaborative role of E2F transcriptional activity and G1 cyclindependent kinase activity in the induction of S phase. Proc. Natl. Acad. Sci. USA 96: 6626-6631.
16. Girard F, Fernandez A and Lamb N (1995) Delayed cyclin A and B1 degradation in non-transformed mammalian cells. J. Cell Sci.108: 2599-2608.
17. Li Y, Jenkins CW, Nichols MA and Xiong Y (1994) Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9: 2261-2268.
18. David-Pfeuty T, Chakrani F, Ory K and Nouvian-Dooghe Y (1996) Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ. 7: 1211-1225.
19. Tolbert D, Lu X, Yin C, Tantama M and Van Dyke T (2002) p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol. Cell. Biol. 22: 370-377.
20. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL and Vousden KH (1998) p14ARF links the tumour suppressors RB and p53. Nature 395: 124-125.
21. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001-5014.
22. O'Connor DJ and Lu X (2000) Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb. Oncogene 19: 2369-2376.
23. Fogal V, Kartasheva NN, Trigiante G, Llanos S, Yap D, Vousden KH and Lu X (2005) ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ. 12: 369-376.
24. Stevens C and La Thangue N (2004) The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair 3: 1071-1079.
25. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T and Lu X (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8: 781-794.
26. Bergamaschi D, Samuels-Lev Y, O'Neil n, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Compargue I, Tomlinson M, Kuwabara P and Lin X (2003) iASPP oncoprotein is key inhibitor of p53 conserved from worm to human. Nat. Genet. 33: 162-167.
27. Slee EA, Gillotin S, Bergamaschi D, Royer C, Llanos S, Ali S, Jin B, Trigiante G and Lu X (2004) The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 23: 9007-9016.
28. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T and Lu X (2004) ASPP1 and ASPP2: Common activators of p53 family members. Mol. Cell. Biol. 24: 1341-1350.
29. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sher CJ and Lowe SW (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434-2442.
30. Gorina S and Pavletich NP (1996) Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274: 1001-1005.
31. Ryan KM and Vousden KH (1998) Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 18: 3692-3698.
32. Kohno K, Izumi H, Uchiumi T, Ashizuka M and Kuwano M (2003) The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 25: 691-698.
33. Wolffe AP (1994) Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. BioEssays 16: 245-251.
34. Yu J, Deng M, Medvedev S, Yang J, Hecht NB and Schultz RM (2004) Transgenic RNAi-mediated reduction of MSY2 in mouse oocytes results in reduced fertility. Dev. Biol. 268: 195-206.
35. Yu J, Hecht NB and Schultz RM (2001) Expression of MSY2 in mouse oocytes and preimplantation embryos. Biol. Reprod. 65: 1260-1270.
36. Tafuri SR, Familari M and Wolffe A P (1993) A mouse Y box protein, MSY1, is associated with paternal mRNA in spermatocytes. J. Biol. Chem. 268: 12213-12220.
37. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K and Kuwano M (1997) Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 417: 390-394.
38. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M and Kohno K (1998) Direct involvement of the YB-1 binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistace 1 gene. J. Biol. Chem. 273: 5997-6000.
39. Stein U, Jurchott K, Walther W, Bergmann S, Schlag PM and Royer HD (2001) Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J. Biol. Chem. 30: 28562-28569.
40. Sorokin AV, Selyutina AA, Skabkin MA, Guryanov SG, Nazimov IV, Richard C, Th'ng J, Yau J, Sorensen PH, Ovchinnikov LP and Evdokimova V (2005) Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J. 24: 3602-3612.
41. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M and Royer HD (2002) Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 97: 278-282.
42. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B and Royer HD (1997) Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 3: 447-450.
43. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP and Ethier SP (2005) Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 24: 3177-3186.
44. Nicholson R, Gee J and Harper M (2001) EGFR and cancer prognosis. Eur. J. Cancer 37: S9-S15.
45. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, Dietel M and Royer HD (2005) YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 65: 4078-4087.
46. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ and Dunn SE (2005) Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292.
47. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M and Kohno K (2000) Direct interaction of p53 with the Y-box binding protein, YB-1: A mechanism for regulation of human gene expression. Oncogene 19: 6194-6202.
48. Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW and Watson J (2003) The Y-box binding protein YB1 is a potential regulator of the p53 tumor suppressor. J. Biol. Chem. 278: 35516-35523.
49. Gartel A and Tyner A (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1: 639-649.
50. Homer C, Knight DA, Hananeia L, Sheard P, Risk J, Lasham A, Royds JA and Braithwaite AW (2005) Y-box factor YB1 controls p53 apoptotic function. Oncogene 24: 8314-8325.
51. Zhang YF, Homer C, Edwards SJ, Hananeia L, Lasham A, Royds J, Sheard P and Braithwaite AW (2003) Nuclear localization of Y-box factor YB1 requires wild-type p53. Oncrogene 22: 2782-2794.
52. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M and Royer HD (2003) YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J. Biol. Chem. 278: 27988-27996.
53. Raffetseder U, Frye B, Rauen T, Jurchott K, Royer HD, Jansen PL and Mertens PR (2003) Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. J. Biol. Chem. 278: 18241-18248.
54. Sakura H, Maekawa T, Imamoto F, Yasuda K and Ishii S (1988) Two human genes isolated by a novel method encode DNA-binding proteins containing a common region of homology. Gene 73: 499-507.
55. En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I and Mertens PR (2005) Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J. Biol. Chem. 280: 7702-7711.
56. Lasham A, Lindridge E, Rudert F, Onrust R and Watson J (2000) Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 252: 1-13.
57. Lu ZH, Books JT and Ley TJ (2005) YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol. Cell. Biol. 25: 4625-4637.
58. Mantovani F, Gostissa M, Collavin L and Del Sal G (2004) KeePin' the p53 family in good shape. Cell Cycle 3: 905-911.
59. Wulf G, Finn G, Suizu F and Lu KP (2005) Phosphorylation-specific prolyl isomerization: Is there an underlying theme? Nat. Cell Biol. 7: 435-441.
60. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR and Sears R (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell. Biol. 6: 308-318.
61. Wulf GM, Liou YC, Ryo A, Lee SW and Lu KP (2002) Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. 277: 47976-47979.
62. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C and Del Sal G (2002) The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853-857.
63. Sun XF, Johannsson O, Hakansson S, Sellberg G, Nordenskjold B, Olsson H and Borg A (1996) A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13: 407-411.
64. Berger M, Stahl N, Del Sal G and Haupt Y (2005) Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol. Cell. Biol. 25: 5380-5388.
65. Xirodimas DP, Saville MK, Bourdon JC, Hay RT and Lane DP (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118: 83-97.
66. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H and Dixit VM (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-92.
67. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R and Benchimol S (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
68. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, Blandino G and Del Sal G (2004) Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol. Cell 14: 625-636.
69. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C and Levrero M (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9: 175-186.
70. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E and Fornace Jr AJ (1999) Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18: 6845-6854.
71. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E and Soddu S (2002) Horneodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4: 11-19.
72. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-64.
73. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC and Kaelin Jr WG (2003) Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410.
74. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M and Blandino G (2005) The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol. Cell 18: 447-459.
75. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, Cesareni G and Melino G (2005) The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 24: 836-848.
76. Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW and Lu KP (2002) PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell. Biol. 22: 5281-5295.
77. You H, Zheng H, Murray SA, Yu Q, Uchida T, Fan D and Xiao ZX (2002) IGF-1 induces Pin1 expression in promoting cell cycle S-phase entry. J. Cell. Biochem. 84: 211-216.
78. Eckerdt F, Yuan J, Saxena K, Martin B, Kappel S, Lindenau C, Kramer A, Naumann S, Daum S, Fischer G, Dikic I, Kaufmann M and Strebhardt K (2005) Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J. Biol. Chem. 280: 36575-36583.
79. Levine A, Hu W and Feng Z (2006) The p53 pathway: What questions remain to be explored? Cell Death Differ. 13: 1027-1036.
80. Keller DM, Zeng SX and Lu H (2003) Interaction of p53 with cellular proteins. In Walker J (ad) p53 protocols. (Totowa: Humana Press Inc.) pp. 121-133.